<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTION 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-23012
---------
NEXSTAR PHARMACEUTICALS, INC.
-------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94306
----------------------------------------------------------------------------
(Address, including zip code, and telephone number, including area
code, of registrant's principal executive offices)
Common Stock, par Value $.01
--------------------------------------------------------------
(Title of each class of securities covered by this Form)
None
---------------------------------------
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate, the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g- 4(a)(1)(i) /X/ Rule 12h-3(b)(1)(i) /X/
Rule 12g4-(a)(1)(ii) / / Rule 12h-3(b)(1)(ii) / /
Rule 12g4-(a)(2)(i) / / Rule 12h-3(b)(2)(i) / /
Rule 12g4-(a)(2)(i) / / Rule 12h-3(b)(2)(ii) / /
Rule 15d-6 / /
Approximate number of holders of record as of the certification or
notice date: ONE
---------------
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934 NeXstar
Pharmaceuticals, Inc. has caused this certification/notice to be signed on
its behalf by the undersigned duly authorized person.
NEXSTAR PHARMACEUTICALS, INC.
By: /s/ Mark L. Perry
-------------------------------------
Name: Mark L. Perry
Title: Secretary and Chief Financial
Officer
Date: August 4, 1999
